STOCK TITAN

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
conferences
Rhea-AI Summary

Ocugen announced that its Chief Scientific Officer, Arun Upadhyay, PhD, will present at the International Society for Cell & Gene Therapy's 2024 Annual Meeting in Vancouver, Canada. The presentation will focus on OCU400, a modifier gene therapy for retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA), targeting over 100 genetic mutations. The presentation will discuss safety and efficacy data from a Phase 1/2 clinical trial. The OCU400 Phase 3 liMeliGhT trial is progressing and aims for BLA and MAA approvals by 2026.

Positive
  • OCU400 targets over 100 mutations for RP and LCA.
  • Phase 3 liMeliGhT trial is underway.
  • Aiming for 2026 BLA and MAA approvals.
  • Presentation at a prestigious international conference.
Negative
  • Efficacy and safety data are still from early-phase trials.
  • Significant time until potential market approval in 2026.

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held May 29-June 1, 2024 in Vancouver, Canada.

“I’m very pleased to present OCU400 data among an organization dedicated to translating cell and gene therapies into safe and effective treatments to improve patients’ lives,” said Dr. Upadhyay. “OCU400 modifier gene therapy represents a breakthrough approach for the potential treatment of broader retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) diseases where more than 100 mutations are involved.”

ISCT provides cutting-edge translational content and an opportunity to connect with global experts from academic institutions, regulatory agencies, and the healthcare industry. Attendees can participate in robust debates, collaborate on developing solutions to sector challenges, and join conversations advancing the field of cell and gene therapy.

Details on Dr. Upadhyay’s presentation are as follows:

Late-Breaking Oral Abstract Session: Safety and Efficacy Results from a Phase 1/2 Clinical Trial of OCU400 Modifier Gene Therapy for Treatment of Retinitis Pigmentosa

Date: Thursday, May 30, 2024
Time: 5-6 p.m. PDT
Location: Room 202-204, Vancouver Convention Centre, West Building

Dr. Upadhyay’s poster will also be available during Poster Networking Session #1 on Wednesday, May 29, 2024 from 7-8:30 p.m. PDT.

The OCU400 Phase 3 liMeliGhT clinical trial is currently underway and on track to meet the Company’s 2026 BLA and MAA approval targets. OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication.

About OCU400
OCU400 is the Company’s gene-agnostic modifier gene therapy product based on nuclear hormone receptor (NHR) gene, NR2E3NR2E3 regulates diverse physiological functions within the retina—such as photoreceptor development and maintenance, metabolism, phototransduction, inflammation and cell survival networks. Through its drive functionality, OCU400 resets altered/affected cellular gene networks and establishes homeostasis—a state of balance, which has the potential to improve retinal health and function in patients with RP. Nearly 300,000 people are affected by RP in the U.S. and EU combined.

About Modifier Gene Therapy
Modifier gene therapy is designed to fulfill unmet medical needs related to retinal diseases, including IRDs, such as RP, LCA and Stargardt disease, as well as multifactorial diseases like dry age-related macular degeneration (dAMD). Our modifier gene therapy platform is based on the use of NHRs, master gene regulators, which have the potential to restore homeostasis — the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, we believe that our modifier gene therapy platform, through its use of NHRs, represents a novel approach that has the potential to address multiple retinal diseases caused by mutations in multiple genes with one product, and to address complex diseases that are potentially caused by imbalances in multiple gene networks. Currently, Ocugen has three modifier gene therapy programs in the clinic: OCU400, OCU410, and OCU410ST. In addition to the OCU400 Phase 3 liMeliGhT clinical trial, the OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy (GA) secondary to dAMD and the OCU410ST Phase 1/2 GARDian clinical trial for Stargardt disease are currently underway. GA affects approximately two to three million people in the U.S. and EU combined and Stargardt disease affects nearly 100,000 people in the U.S. and EU combined.

About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com

 


FAQ

What is Ocugen's stock symbol?

OCGN

When is Ocugen presenting at the ISCT 2024 Annual Meeting?

May 29-June 1, 2024

What gene therapy will Ocugen present at the ISCT 2024?

OCU400 for retinitis pigmentosa and Leber congenital amaurosis

What phase is OCU400 currently in?

Phase 3 liMeliGhT trial

When does Ocugen aim to achieve BLA and MAA approvals for OCU400?

By 2026

Ocugen, Inc.

NASDAQ:OCGN

OCGN Rankings

OCGN Latest News

OCGN Stock Data

392.47M
252.38M
1.45%
10.33%
16.95%
Sanitary Paper Product Manufacturing
Manufacturing
Link
United States of America
MALVERN

About OCGN

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.